Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. filed a Form 8-K on November 3, 2015, to announce its financial results for the third quarter ended September 30, 2015. The filing incorporates a press release (Exhibit 99.1) and details a conference call scheduled for November 4, 2015.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves as a notification of the release of Q3 2015 results rather than a detailed financial analysis.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding plans, strategies, and intentions, which are subject to risks and uncertainties. These risks are referenced as being detailed in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014. The Company explicitly states it undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q3 2015 revenue and net loss figures.
- Verify cash position and liquidity metrics in the full press release or subsequent 10-Q filing.
- Consult the 2014 Form 10-K (Item 1A) for a comprehensive list of risk factors applicable to forward-looking statements.
- Confirm the date and access details for the archived webcast of the November 4, 2015 conference call.